K. Appenteng

First name
Last name
Arana, A. ., Margulis, A. V., McQuay, L. J., Ziemiecki, R. ., Bartsch, J. L., Rothman, K. J., … Perez-Gutthann, S. . (2018). Variation in Cardiovascular Risk Related to Individual Antimuscarinic Drugs Used to Treat Overactive Bladder: A UK Cohort Study. Pharmacotherapy. http://doi.org/10.1002/phar.2121
Margulis, A. V., Linder, M. ., Arana, A. ., Pottegard, A. ., Berglind, I. A., Bui, C. L., … Hallas, J. . (2018). Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United Kingdom. PLoS One. http://doi.org/10.1371/journal.pone.0204456
Arana, A. ., Margulis, A. V., Varas-Lorenzo, C. ., Bui, C. L., Gilsenan, A. ., McQuay, L. J., … Perez-Gutthann, S. . (2020). Validation of cardiovascular outcomes and risk factors in the Clinical Practice Research Datalink in the United Kingdom. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.5150
Heintjes, E. M., Bezemer, I. D., Prieto-Alhambra, D. ., Smits, E. ., Booth, H. P., Dedman, D. ., … van Beest, F. J. A. P.-. (2020). Evaluating the Effectiveness of an Additional Risk Minimization Measure to Reduce the Risk of Prescribing Mirabegron to Patients with Severe Uncontrolled Hypertension in Four European Countries. Clin Epidemiol. http://doi.org/10.2147/clep.s242065
Phiri, K. ., Hallas, J. ., Linder, M. ., Margulis, A. ., Suehs, B. ., Arana, A. ., … Seeger, J. . (2021). A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder. Curr Med Res Opin. http://doi.org/10.1080/03007995.2021.1891035
Hoffman, V. ., Hallas, J. ., Linder, M. ., Margulis, A. V., Suehs, B. T., Arana, A. ., … Seeger, J. D. (2021). Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study. Drug Saf. http://doi.org/10.1007/s40264-021-01095-7